FDA Raising Approval Bar For NSAID/PPI Combos; Endpoints Under Review
Executive Summary
FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim
You may also be interested in...
FDA Plan To Harmonize Advice On NSAID GI Injury Assessments Draws Cmte. Rebuff
FDA’s bid to harmonize two review divisions’ regulatory approaches to assessing and preventing gastrointestinal toxicity caused by non-steroidal anti-inflammatory drugs has been thrown a curve by the agency’s outside experts.
FDA Plan To Harmonize Advice On NSAID GI Injury Assessments Draws Cmte. Rebuff
FDA’s bid to harmonize two review divisions’ regulatory approaches to assessing and preventing gastrointestinal toxicity caused by non-steroidal anti-inflammatory drugs has been thrown a curve by the agency’s outside experts.
PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.